IP Library › Granted Patent US 12,221,603
Granted Patent B2
US 12,221,603 · App. 18/329,659 · Granted Feb 11, 2025

System and method for production of on-demand proteins in a portable unit for point of care delivery

Inventors: Govind Rao (Ellicott City, MD); Yordan Kostov (Columbia, MD); Leah Tolosa (Columbia, MD); Xudong Ge (Woodstock, MD); Douglas Frey (Ellicott City, MD)
Assignee: University of Maryland, Baltimore County
C12M47/10C12M41/12C12M47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,221,603
App. No.
18/329,659
Granted
Feb 11, 2025
Kind
B2
Abstract

A portable and mobile bioprocessing system and method for protein manufacturing that is compact, integrated and suited for on-demand production of any type of proteins and for delivery of the produced proteins to patients or for assay purposes. The portable system and method can also be used for efficient on-demand production of any type of protein with point-of-care delivery.

Claims (28)

1. A method of treating anemia in a patient in need thereof, said method comprising administering Erythropoetin (EPO) to the patient, wherein the EPO is synthesized on-demand in a bioprocessing system using cell-free protein expression, said bioprocessing system comprising:

a production module for producing non-purified EPO protein;

a purification module for receiving the non-purified EPO protein from the production module and for purifying the EPO protein; and

a processor for controlling and/or monitoring at least one of the production module and the purification module.

2. The method of claim 1 , wherein the EPO can be administered continuously or as a bolus to the patient.

3. The method of claim 1 , wherein the purification module comprises:

a chromatography component for receiving the non-purified EPO from the production module and for outputting purified EPO; and

a diafiltration component for receiving the purified EPO from the chromatography component and for outputting further purified EPO, wherein the diafiltration component comprises a product section for receiving the purified EPO from the chromatography component and a buffer section for receiving a buffer solution.

4. The method of claim 3 , wherein the buffer solution is free of dithiothreitol (DTT).

5. The method of claim 1 , wherein the production module comprises a reaction mixture comprising a nucleotide template for production of the EPO, monomers for the EPO to be synthesized, co-factors, enzymes and reagents that are necessary for the synthesis.

6. The method of claim 1 , wherein the production module comprises a bioreactor for cell-free EPO expression and at least one sensor for monitoring at least one of conductivity, temperature, pH, oxygen and CO 2 .

7. The method of claim 1 , wherein the production module and purification module each comprise a heating and cooling element for controlling the temperature of solution inside the respective modules.

8. The method of claim 1 , wherein the bioprocessing system further comprises a fluid storage and dispensing module for storing solutions used by the production module for EPO expression, for storing waste product produced by the purification module, and for storing EPO output by the purification module.

9. The method of claim 1 , wherein potency/activity of the purified EPO is at least 55% or more of the initial activity for at least 3 days at temperature from above 0° C. to about 30° C.

10. A method of treating a clot or achieving thrombolysis in a patient in need thereof, said method comprising administering Streptokinase to the patient, wherein the Streptokinase is synthesized on-demand in a bioprocessing system using cell-free protein expression, said bioprocessing system comprising:

a production module for producing non-purified Streptokinase protein;

a purification module for receiving the non-purified Streptokinase protein from the production module and for purifying the Streptokinase protein; and

a processor for controlling and/or monitoring at least one of the production module and the purification module.

11. The method of claim 10 , wherein the Streptokinase can be administered continuously or as a bolus to the patient.

12. The method of claim 10 , wherein the purification module comprises:

a chromatography component for receiving the non-purified Streptokinase protein from the production module and for outputting purified Streptokinase protein; and

a diafiltration component for receiving the purified Streptokinase protein from the chromatography component and for outputting further purified Streptokinase protein, wherein the diafiltration component comprises a product section for receiving the purified Streptokinase protein from the chromatography component and a buffer section for receiving a buffer solution.

13. The method of claim 12 , wherein the buffer solution is free of dithiothreitol (DTT).

14. The method of claim 10 , wherein the production module comprises a reaction mixture comprising a nucleotide template for production of the Streptokinase, monomers for the Streptokinase to be synthesized, co-factors, enzymes and reagents that are necessary for the synthesis.

15. The method of claim 10 , wherein the production module comprises a bioreactor for cell-free Streptokinase protein expression and at least one sensor for monitoring at least one of conductivity, temperature, pH, oxygen and CO 2 .

16. The method of claim 10 , wherein the production module and purification module each comprise a heating and cooling element for controlling the temperature of solution inside the respective modules.

17. The method of claim 10 , wherein the bioprocessing system further comprises a fluid storage and dispensing module for storing solutions used by the production module for Streptokinase protein expression, for storing waste product produced by the purification module, and for storing Streptokinase protein output by the purification module.

18. The method of claim 10 , wherein potency/activity of the purified Streptokinase is at least 55% or more of the initial activity for at least 3 days at temperature from above 0° C. to about 30° C.

Continuity (7)
Division 17376439 · Jul 15, 2021
Division 16506079 · Jul 9, 2019
Division 15966609 · Apr 30, 2018
Continuation 15095305 · Apr 11, 2016
Continuation In Part 13823911
Provisional Application 61450191 · Mar 8, 2011
Related Publication 20230323277A1 · Oct 12, 2023
References Cited (28)
US 5968767A · Sheikh et al. · 1999 [cited by applicant]
US 6642024B1 · Pennica · 2003 [cited by applicant]
US 6670173B1 · Schels et al. · 2003 [cited by applicant]
US 6673532B2 · Rao · 2004 [cited by applicant]
US 6905843B1 · Endo et al. · 2005 [cited by applicant]
US 6946075B2 · Kopf · 2005 [cited by applicant]
US 7041493B2 · Rao · 2006 [cited by applicant]
US 7485454B1 · Jury et al. · 2009 [cited by applicant]
US 9163272B2 · Park et al. · 2015 [cited by applicant]
US 9388373B2 · Rao · 2016 [cited by applicant]
US 9982227B2 · Rao et al. · 2018 [cited by applicant]
US 10435664B2 · Rao · 2019 [cited by applicant]
US 11702625B2 · Rao et al. · 2023 [cited by applicant]
US 20080248521A1 · Knapp et al. · 2008 [cited by applicant]
US 20080269468A1 · Vogel et al. · 2008 [cited by applicant]
US 20080287656A1 · Peters et al. · 2008 [cited by applicant]
US 20090178495A1 · Steigmiller et al. · 2009 [cited by applicant]
US 20100298172A1 · Desmond et al. · 2010 [cited by applicant]
US 20110065084A1 · Rao et al. · 2011 [cited by applicant]
US 20130280797A1 · Rao et al. · 2013 [cited by applicant]
WO WO2005063808A1 · 2005 [cited by examiner]
WO WO20080066583A1 · 2008 [cited by applicant]
WO WO2016019350A2 · 2016 [cited by applicant]
Salehi, Amin S. et al. “Cell-free protein synthesis of a cytotoxic cancer therapeutic: Onconase production and a just-add-water cell-free system.” Biotechnology Journal, 2015, doi.1002/biot.201500237. [cited by applicant]
Sun, Zachary et al. “Protein degradation in a TX-TL cell-free expression system using ClpXP protease.” Technical Report, Jul. 8, 2014, http://www.cds.caltech.edu/˜murray/papers/sksm14-clpxp.html. [cited by applicant]
Pierce (Protein stability and Storage, Technical resource, 2005, updated Jul. 14, 15). [cited by applicant]
Office Action, U.S. Appl. No. 16/660,993; Dated Apr. 15, 2020. [cited by applicant]
K.A. Calhoun, J.R. Swartz, Energy Systems for ATP Regeneration in Cell-Free Protein Synthesis Reactions, in: In Vitro Transcription and Translation Protocols, 2nd edition, Guido Grandi ed., 2007 Humana Press Inc., New J… [cited by applicant]